TY  -  JOUR
AU  -  Nelli, Fabrizio
AU  -  Fabbri, Maria Agnese
AU  -  Moscetti, Luca
AU  -  Sperduti, Isabella
AU  -  Gamucci, Teresa
AU  -  Mansueto, Giovanni
AU  -  Signorelli, Carlo
AU  -  Cortesi, Enrico
AU  -  Martelli, Olga
AU  -  Natoli, Clara
AU  -  Angelini, Francesco
AU  -  Ruggeri, Enzo Maria
T1  -  Long-term outcome of pemetrexed maintenance
for advanced nonsquamous non-small-cell lung cancer:
a real-world observational cohort study
PY  -  2020
Y1  -  2020-12-01
DO  -  10.1701/3509.34967
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  111
IS  -  12
SP  -  761
EP  -  768
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/04/15
UR  -  http://dx.doi.org/10.1701/3509.34967
N2  -  Summary. Introduction. Pemetrexed maintenance significantly improved progression-free survival (PFS) and overall survival (OS) in advanced nonsquamous non-small-cell lung cancer (NSCLC) patients not progressing after induction chemotherapy. Objectives. This study is aimed at examine the association of various clinical factor and survival in a real-world cohort analysis. Materials and methods. One hundred ninety-four patients were included and classified as “PM” cohort (“Pemetrexed Maintenance”, including patients given with pemetrexed maintenance after induction chemotherapy, n=112), and “noPM” cohort (“no Pemetrexed Maintenance” including those discontinuing pemetrexed, n=82). Results. The median PFS was 8.8 and 5.4 months in the PM and noPM cohorts, respectively (p=0.001). The median OS was 19.6 months in the “PM” cohort and 13.2 months in the “noPM” cohort (p<0.02). In the multivariate analysis, ECOG Performance Status (PS) 0 and maintenance therapy were independently associated with improved PFS and OS. A longer median PFS was reported in patients given ≥5 cycles of pemetrexed maintenance (p<0.01). Discussion. These results further confirm the survival benefit of pemetrexed maintenance in a real-word population. All eligible advanced NSCLC patients should be strongly considered for at least 5 of pemetrexed maintenance.
ER  -